Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Co-Diagnostics (CODX) Misses Q4 EPS by 5c, Revenues Beat
March 25, 2021 4:03 PM EDTCo-Diagnostics (NASDAQ: CODX) reported Q4 EPS of $0.43, $0.05 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $27.1 million versus the consensus estimate of $24.99 million.
Fourth Quarter 2020 Financial Results:
Revenue of $27.1 million, primarily due to sales of the Logix Smart COVID-19 TestGross profit increased to $22.8 million, representing 84.1% of consolidated revenue due to improved product mix as compared... More